These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8829723)

  • 1. Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine.
    Mellers JD; Quinn NP; Ron MA
    Br J Psychiatry; 1995 Oct; 167(4):522-6. PubMed ID: 8829723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression antedating the onset of Parkinson's disease.
    Fukunishi I; Hosokawa K; Ozaki S
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):7-11. PubMed ID: 1753493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
    Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
    Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychopathological correlates of dopaminergic disturbances in major depression.
    Pitchot W; Hansenne M; Moreno AG; von Frenckell R; Ansseau M
    Neuropsychobiology; 1990-1991; 24(4):169-72. PubMed ID: 2135707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic function in panic disorder: comparison with major and minor depression.
    Pitchot W; Ansseau M; Gonzalez Moreno A; Hansenne M; von Frenckell R
    Biol Psychiatry; 1992 Dec; 32(11):1004-11. PubMed ID: 1467380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin and cortisol responses to fenfluramine in Parkinson's disease.
    Kostić VS; Lecić D; Doder M; Marinković J; Filipović S
    Biol Psychiatry; 1996 Oct; 40(8):769-75. PubMed ID: 8894070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suicidal behavior and growth hormone response to apomorphine test.
    Pitchot W; Hansenne M; Moreno AG; Ansseau M
    Biol Psychiatry; 1992 Jun; 31(12):1213-9. PubMed ID: 1391282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression in Parkinson's disease: a biochemical model.
    Sano M; Stern Y; Cote L; Williams JB; Mayeux R
    J Neuropsychiatry Clin Neurosci; 1990; 2(1):88-92. PubMed ID: 2136066
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine.
    Zemlan FP; Hirschowitz J; Sautter F; Garver DL
    Psychiatry Res; 1986 Jul; 18(3):239-55. PubMed ID: 2875478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease, personality, and dopamine.
    Menza MA; Forman NE; Goldstein HS; Golbe LI
    J Neuropsychiatry Clin Neurosci; 1990; 2(3):282-7. PubMed ID: 2136087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Parkinson's disease and psychoses].
    Bizzarri JV; Giupponi G; Maniscalco I; Schroffenegger P; Conca A; Kapfhammer HP
    Neuropsychiatr; 2015; 29(1):1-13. PubMed ID: 25586068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
    Dépatie L; Lal S
    J Psychiatry Neurosci; 2001 May; 26(3):203-20. PubMed ID: 11394190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-motor symptoms in Parkinson's disease: cognition and behavior].
    Bonnet AM; Czernecki V
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Sep; 11(3):295-304. PubMed ID: 24026132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations.
    Ramírez-Ruiz B; Junqué C; Martí MJ; Valldeoriola F; Tolosa E
    Mov Disord; 2006 Sep; 21(9):1483-7. PubMed ID: 16705661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence.
    Borgemeester RW; Lees AJ; van Laar T
    Parkinsonism Relat Disord; 2016 Jun; 27():35-40. PubMed ID: 27132157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.
    Zemlan FP; Hirschowitz J; Garver DL
    Arch Gen Psychiatry; 1986 Dec; 43(12):1162-7. PubMed ID: 3778112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.
    Friess E; Kuempfel T; Winkelmann J; Schmid D; Uhr M; Rupprecht R; Holsboer F; Trenkwalder C
    Arch Neurol; 2001 Feb; 58(2):241-6. PubMed ID: 11176962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine supersensitivity and hormonal status in puerperal psychosis.
    Meakin CJ; Brockington IF; Lynch S; Jones SR
    Br J Psychiatry; 1995 Jan; 166(1):73-9. PubMed ID: 7894880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine evaluation of catecholaminergic neurotransmission in mania.
    Ansseau M; von Frenckell R; Cerfontaine JL; Papart P; Franck G; Timsit-Berthier M; Geenen V; Legros JJ
    Psychiatry Res; 1987 Nov; 22(3):193-206. PubMed ID: 2829258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.
    Happe S; Tings T; Koch W; Welsch J; Helmschmied K; Baier PC; Meller J; Wuttke W; Paulus W; Tatsch K; Trenkwalder C
    J Neural Transm (Vienna); 2007; 114(5):589-94. PubMed ID: 17187291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.